Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

The efficacy and safety of a topical alprostadil cream, Alprox-TD®, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED

International Journal of Impotence Research volume 15, pages 10–17 (2003)Cite this article

Abstract

In two multicenter, placebo controlled, phase 2 studies, patients with mild-to-moderate (n=161, Study 1) or severe (n=142, Study 2) erectile dysfunction (ED) were randomized to receive placebo, 0.05, 0.1, or 0.2 mg (Study 1) or placebo, 0.1, 0.2, or 0.3 mg (Study 2) of topically applied alprostadil (containing a proprietary skin permeation enhancer). The primary efficacy end point in both studies was the change in erectile function (EF) score from baseline to final visit. The changes from baseline for EF scores were −0.8±1.1, 1.8±1.1, 0.7±1.2, and 3.7±1.2 (P<0.01; Study 1) and 2.7±1.3, 6.29±1.4, 6.49±1.5, and 9.44±1.5 (P<0.001; Study 2) for ascending dose groups in each study. Topical alprostadil was well tolerated with the most common adverse event being urogenital pain. These results suggest this topical alprostadil formulation may be a potentially useful agent for the treatment of ED.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. McKinlay JB . The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12(Suppl 4): S6–S11.

    Article  Google Scholar 

  2. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

  3. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1988; 338: 1397–1404.

    Article  Google Scholar 

  4. Linet O, Ogrinc FG, Alprostadil Study Group. Efficacy and safety of intracavernosal Alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873–877.

    Article  CAS  Google Scholar 

  5. Porst H, Buvat J, Meuleman E, Michal V, Wagner G . Intracavernous alprostadil alfadex—an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 1998; 10: 225–231.

    Article  CAS  Google Scholar 

  6. Padma-Nathan H, Hellstrom WJG, Kaiser FE et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336: 1–7.

    Article  CAS  Google Scholar 

  7. Porst H . Transurethral Alprostadil with MUSETM (medicated urethral system for erection) vs intracavernosal Alprostadil—a comparative study of 103 patients with erectile dysfunction. Int J Impot Res 1997; 9: 187–192.

    Article  CAS  Google Scholar 

  8. Porst H . Review Article. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802–815.

    Article  CAS  Google Scholar 

  9. Adaikin PG, Kottegoda SR, Ratnam SS . A possible role for prostaglandin E1 in human penile erection. In: Abstract Book Second World Meeting on Impotence. Prague, 1986; Abstract 2.6.

    Google Scholar 

  10. Shabsigh R, Padma-Nathan H, Gittleman M et al. Intracavernous alprostadil alfadex (edex/viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 477.

    Article  CAS  Google Scholar 

  11. Kim ED, McVary KT . Topical prostaglandin-E1 for the treatment of erectile dysfunction. J Urol 1995; 153: 1828.

    Article  CAS  Google Scholar 

  12. Montorsi F, Guazzoni C, Barbieri L et al. Clinical and hemodynamic effects of transdermal alprostadil for mild arteriogenic impotence: a double-blind placebo controlled study. Int J Impot Res 1995; 7: 10.

    Google Scholar 

  13. Goldstein I, Payton TR, Schechter PJ . A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (topiglan) for the in-office treatment of erectile dysfunction. Urology 2001; 57: 301.

    Article  CAS  Google Scholar 

  14. Rosen RC, Riley A, Wagner G et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822.

    Article  CAS  Google Scholar 

  15. Padma-Nathan H, McMurray JG, Pullman WE et al. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Imp Res 2001; 13: 2.

    Article  CAS  Google Scholar 

  16. Padma-Nathan H et al. Hemodynamic effects of intraurethral Alprostadil: The Medicated Urethral System for Erection (MUSE). J Urol 1994; 151: 345A (469).

    Google Scholar 

  17. Porst HRR, Padma-Nathan H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192–199.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

These studies were supported by a grant from NexMed Inc.

Author information

Authors and Affiliations

  1. The Male Clinic, Beverly Hills, CA, USA

    H Padma-Nathan

  2. Northeast Indiana Research, Fort Wayne, IN, USA

    C Steidle

  3. Symbiance Inc, Princeton, NJ, USA

    S Salem

  4. NexMed Inc, Robbinsville, NJ, USA

    N Tayse, J Yeager & R Harning

Authors
  1. H Padma-Nathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Steidle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Tayse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Yeager
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Harning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Padma-Nathan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Padma-Nathan, H., Steidle, C., Salem, S. et al. The efficacy and safety of a topical alprostadil cream, Alprox-TD®, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. Int J Impot Res 15, 10–17 (2003). https://doi.org/10.1038/sj.ijir.3900940

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900940

Keywords

This article is cited by

Search

Advanced search

Quick links